A2000 |
Cetuximab (anti-EGFR)
|
Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW:145.781 KD. |
-
Adv Sci (Weinh), 2021, e2103360
-
Nat Commun, 2021, 12(1):2335
-
Environ Health Perspect, 2021, 129(2):27005
|
|
A2018New |
Panitumumab (anti-EGFR)
|
Panitumumab (anti-EGFR, ABX-EGF) is a recombinant, fully human IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR). |
|
|
E0368New |
DZD9008
|
DZD9008 is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR. |
|
|
S0070 |
Gefitinib-based PROTAC 3
|
Gefitinib-based PROTAC 3 which conjugates an EGFR binding element to a VHL ligand via a linker induces degradation of EGFR and mutants with DC50 of 11.7 nM and 22.3 nM in HCC827(Exon 19 del) and H3255 (L858R) cells, respectively. |
|
|
S0151 |
AG-1557
|
AG-1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. |
|
|
S0360 |
EGFR Inhibitor
|
EGFR inhibitor, a cell permeable, 4,6-disubstituted pyrimidine compound, is a highly selevtive inhibitor of EGFR kinase with IC50 of 21 nM. EGFR inhibitor directly depolymerizes microtubules and is used as a chemical probe to investigate both the EGFR pathway and microtubule dynamics. |
|
|
S0711 |
Canertinib dihydrochloride
|
Canertinib (CI-1033, PD-183805, compound 18) dihydrochloride is a potent and irreversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Canertinib dihydrochloride inhibits cellular EGFR and ErbB2 autophosphorylation with IC50 of 7.4 nM and 9 nM, respectively. |
-
Acta Physiol (Oxf), 2021, 10.1111/apha.13661
-
Sci Rep, 2017,
-
BMC Cancer, 2017,
|
|
S1006 |
Saracatinib (AZD0530)
|
Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3. |
-
Front Pharmacol, 2022, 13:807440
-
Hum Cell, 2022, 10.1007/s13577-022-00671-y
-
Cancer Cell, 2021, S1535-6108(21)00383-4
|
|
S1011 |
Afatinib (BIBW2992)
|
Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFRwt, EGFR L858R , EGFR L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy. |
-
Nature, 2022, 603(7900):335-342
-
Cancer Cell, 2022, S1535-6108(21)00662-0
-
Nat Immunol, 2022, 23(2):251-261
|
|
S1019 |
Canertinib (CI-1033)
|
Canertinib (CI-1033, PD183805) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3. |
-
Hum Cell, 2022, 10.1007/s13577-022-00671-y
-
Nat Chem Biol, 2021, 10.1038/s41589-021-00947-8
-
Acta Physiol (Oxf), 2021, 10.1111/apha.13661
|
|
S1023 |
Erlotinib HCl (OSI-744)
|
Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
-
Sci Adv, 2022, 8(4):eabi7711
-
Cancer Res, 2022, canres.2445.2021
-
Ther Adv Med Oncol, 2022, 14:17588359221079125
|
|
S1025 |
Gefitinib (ZD1839)
|
Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway. |
-
Mol Cancer, 2022, 21(1):43
-
Sci Adv, 2022, 8(4):eabi7711
-
Cell Death Dis, 2022, 13(2):136
|
|
S1028 |
Lapatinib (GW-572016) Ditosylate
|
Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. |
-
Nat Chem Biol, 2022, 10.1038/s41589-022-00984-x
-
Breast Cancer Res, 2022, 24(1):18
-
Mol Cancer Ther, 2022, molcanther.0320.2021
|
|
S1046 |
Vandetanib (ZD6474)
|
Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS). |
-
Cancer Res, 2022, canres.1397.2021
-
Hum Cell, 2022, 10.1007/s13577-022-00671-y
-
Cell Rep Med, 2022, 3(1):100492
|
|
S1054 |
AG99
|
AG99 (Tyrphostin 46,Tyrphostin A46,Tyrphostin B40) is a potent and selective inhibitor of EGFR. |
|
|
S1056 |
AC480 (BMS-599626)
|
AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc. Phase 1. |
-
Genome Med, 2020, 18;12(1):17
-
PLoS Genet, 2016, 12(9):e1006279
-
Asian J Androl, 2016, 10.4103/1008-682X
|
|
S1079 |
PD153035 HCl
|
PD153035 HCl (SU-5271 HCl, AG1517 HCl, ZM 252868 HCl) is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM in cell-free assays; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src. |
-
Int J Mol Sci, 2021, 22(8)3945
-
FEBS Lett, 2021, 595(5):563-576
-
FEBS Lett, 2021, 10.1002/1873-3468.14032
|
|
S1143 |
AG-490 (Tyrphostin B42)
|
AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src. |
-
J Exp Med, 2022, 219(4)e20211498
-
J Headache Pain, 2022, 23(1):25
-
Mol Neurobiol, 2022, 59(5):3280-3293
|
|
S1167 |
CP-724714
|
CP-724714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc in cell-free assays. Phase 2. |
-
Biochem J, 2021, BCJ20210173
-
Int J Mol Sci, 2020, 22(1)E82
-
NPJ Breast Cancer, 2020, 6:30
|
|
S1170 |
WZ3146
|
WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I). |
-
Aging (Albany NY), 2020, 12(19):19022-19044
|
|
S1173 |
WZ4002
|
WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM in BaF3 cell line; does not inhibit ERBB2 phosphorylation (T798I). |
-
Cancers (Basel), 2021, 13(16)4133
-
Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w
-
Cell Res, 2020, 10.1038/s41422-020-00409-1
|
|
S1179 |
WZ8040
|
WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I). |
-
Biochemistry, 2018, 57(8):1369-1379
-
Nat Commun, 2016, 7:10690
|
|
S1194 |
CUDC-101
|
CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1. |
-
Cancer Sci, 2020, 112(1):133-143
-
Anticancer Drugs, 2020, 31(2):158-168
-
NPJ Breast Cancer, 2020, 6:30
|
|
S1342 |
Genistein (NPI 031L)
|
Genistein (NPI 031L), a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12μM or by insulin with IC50 of 19 μM. |
-
Hum Cell, 2022, 10.1007/s13577-022-00671-y
-
Adv Sci (Weinh), 2021, e2103360
-
Nat Chem Biol, 2021, 10.1038/s41589-021-00772-z
|
|
S1392 |
Pelitinib (EKB-569)
|
Pelitinib (EKB-569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM. Pelitinib (EKB-569) also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282 nM, 800 nM and 1255 nM, respectively. Phase2. |
-
Sci Rep, 2022, 12(1):2928
-
Mol Cancer Ther, 2020, 5;molcanther.1131.2019
-
Nat Cell Biol, 2019, 21(6):778-790
|
|
S1486 |
AEE788 (NVP-AEE788)
|
AEE788 (NVP-AEE788) is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2. |
-
Cell Rep Med, 2022, 3(1):100492
-
Genome Med, 2020, 18;12(1):17
-
Mol Pharmacol, 2019, 95(5):528-536
|
|
S2111 |
Lapatinib (GW-572016)
|
Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death. |
-
Cancer Discov, 2022, 12(1):204-219
-
Cell Metab, 2022, 34(1):90-105.e7
-
Nat Chem Biol, 2022, 10.1038/s41589-022-00984-x
|
|
S2115 |
RG 13022
|
RG 13022 (Tyrphostin RG13022) inhibits the autophosphorylation reaction of the EGF receptor in immunoprecipitates with IC50 of 4 µM. |
|
|
S2150 |
Neratinib (HKI-272)
|
Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM in cell-free assays; weakly inhibits KDR and Src, no significant inhibition to Akt, CDK1/2/4, IKK-2, MK-2, PDK1, c-Raf and c-Met. Phase 3. |
-
Cell Metab, 2022, 34(1):90-105.e7
-
JCO Precis Oncol, 2022, 6:e2100325
-
Biomedicines, 2022, 10(3)638
|
|
S2185 |
Allitinib (AST-1306)
|
Allitinib (AST-1306, AST-6) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases. |
-
Front Cell Dev Biol, 2020, 8:605110
-
Cell Signal, 2020, 65:109439
-
Life Sci, 2020, 15;251:117634
|
|
S2192 |
Sapitinib (AZD8931)
|
Sapitinib (AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM in cell-free assays, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt. Phase 2. |
-
Cell Rep, 2021, 35(11):109233
-
Cancer Lett, 2021, 519:328-342
-
Nature, 2020, 584(7822):608-613
|
|
S2205 |
OSI-420
|
OSI-420 (DesMethyl Erlotinib, CP-473420) is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM). |
-
Immunol Res, 2022, 10.1007/s12026-022-09262-3
-
Hum Cell, 2022, 10.1007/s13577-022-00671-y
-
J Chromatogr B Analyt Technol Biomed Life Sci, 2021, 1166:122554
|
|
S2250 |
(-)-Epigallocatechin Gallate
|
(-)-Epigallocatechin Gallate(EGCG) is the main catechin extraction of green tea that inhibits telomerase and DNA methyltransferase. EGCG blocks the activation of EGF receptors and HER-2 receptors. ECGG inhibits fatty acid synthase and glutamate dehydrogenase activity. |
-
Exp Cell Res, 2022, 411(1):113000
-
Int J Mol Med, 2022, 49(1)11
-
EMBO Rep, 2021, e53166
|
|
S2406 |
Chrysophanic Acid
|
Chrysophanic Acid (Chrysophanol) a natural anthraquinone isolated from Dianella longifolia, is a EGFR/mTOR pathway inhibitor. |
-
Cell Prolif, 2020, e12871
-
Naunyn Schmiedebergs Arch Pharmacol, 2019, 10.1007/s00210-019-01746-8
|
|
S2554 |
Daphnetin
|
Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities. |
-
Sci Rep, 2021, 11(1):11491
-
Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7
-
Int Immunopharmacol, 2019, 72:195-203
|
|
S2727 |
Dacomitinib (PF-00299804)
|
Dacomitinib (PF299804, PF299) is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM in a cell-free assay. Dacomitinib inhibits ERBB2 and ERBB4 with IC50 of 45.7 nM and 73.7 nM, respectively. Dacomitinib is effective against NSCLCs with EGFR or ERBB2 mutations (resistant to gefitinib) as well as those harboring the EGFR T790M mutation. Dacomitinib inhibits cell growth and induces apoptosis. Phase 2. |
-
Int J Biol Sci, 2022, 18(5):2047-2059
-
BMC Pulm Med, 2022, 22(1):36
-
Cancer Med, 2022, 10.1002/cam4.4504
|
|
S2728 |
AG-1478 (Tyrphostin AG-1478)
|
AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA). |
-
Elife, 2022, 11e69906
-
Int J Biol Sci, 2022, 18(1):349-359
-
J Am Chem Soc, 2021, 10.1021/jacs.1c05386
|
|
S2752 |
HER2-Inhibitor-1
|
HER2-Inhibitor-1 is an analog of ARRY-380. ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR. |
-
Commun Biol, 2021, 4(1):762
|
|
S2755 |
Varlitinib
|
Varlitinib (ARRY334543) is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM, respectively. Phase 2. |
-
Cell Rep Med, 2022, 3(1):100492
-
Pharmaceutics, 2019, 11(11)
-
Pharmaceutics, 2018, 10(3)
|
|
S2784 |
TAK-285
|
TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1. |
-
Oncotarget, 2020, 11(46):4224-4242
-
Mol Pharmacol, 2019, 95(5):528-536
-
Sci Signal, 2018, 11(549)
|
|
S2867 |
WHI-P154
|
WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation. |
-
Sci Rep, 2022, 12(1):7
-
Am J Transplant, 2021, 21(7):2360-2371
-
J Med Chem, 2020, 31
|
|
S2895 |
Tyrphostin 9
|
Tyrphostin 9 (SF 6847, RG-50872) is firstly designed as an EGFR inhibitor with IC50 of 460 μM, but is also found to be more potent to PDGFR with IC50 of 0.5 μM. |
-
Cell Rep, 2022, 38(10):110475
|
|
S2922 |
Icotinib (BPI-2009H)
|
Icotinib (BPI-2009H) is a potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). |
-
Cell Rep Med, 2022, 3(1):100492
-
Nat Cell Biol, 2019, 21(8):1027-1040
-
Oncogene, 2017, 36(45):6235-6243
|
|
S3759 |
Norcantharidin
|
Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers. |
|
|
S4667 |
Lidocaine hydrochloride
|
Lidocaine hydrochloride (Lidothesin, Lignocaine, Xyloneural) is an inhibitor of epidermal growth factor receptor (EGFR) and has antiproliferative effect on human tongue cancer cells. Lidocaine hydrochloride is a local anesthetic and cardiac depressant used as an antiarrhythmia agent. |
-
Exp Ther Med, 2021, 21(5):424
|
|
S5078 |
Osimertinib mesylate
|
Osimertinib mesylate (AZD9291) is the mesylate form of osimertinib, which is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug. |
-
Nature, 2022, 603(7900):335-342
-
Mol Cancer, 2022, 21(1):43
-
Cancers (Basel), 2022, 14(6)1512
|
|
S5098 |
Gefitinib hydrochloride
|
Gefitinib (ZD1839) is an EGFR inhibitor with IC50s of 15.5 nM and 823.3 nM for WT EGFR and EGFR (858R/T790M), respectively. |
-
Mol Cancer, 2022, 21(1):43
-
Ther Adv Med Oncol, 2022, 14:17588359221079125
-
Cancers (Basel), 2022, 14(3)639
|
|
S6509 |
AG 494
|
AG-494, a member of the tyrphostin family of tyrosine kinase inhibitors, is a potent inhibitor of EGF receptor autophosphorylation (IC50=1.2 μM) and EGF-dependent cell growth (IC50=6 μM). |
|
|
S6523 |
RG14620
|
RG14620 (Tyrphostin RG14620), an EGFR inhibitor of the tyrphostin family, directly inhibits the transport function of ABCG2/BCRP. |
|
|
S6525 |
AG 555
|
AG-555 (Tyrphostin B46) is an inhibitor of tyrosine kinase, interacts directly with topoisomerase I, thus preventing DNA relaxation. It inhibits EGFR with an IC50 of 0.7 μM. |
|
|
S6541 |
MTX-211
|
MTX-211 is a first-in-class dual inhibitor of PI3K and EGFR kinase. |
|
|
S6546 |
PD153035
|
PD153035 is a specific and potent inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase (Ki = 5.2 pM). |
-
Nature, 2021, 10.1038/s41586-020-03085-8
-
Int J Mol Sci, 2021, 22(8)3945
-
FEBS Lett, 2021, 595(5):563-576
|
|
S6698 |
TQB3804 (EGFR-IN-7)
|
TQB3804 (EGFR-IN-7) is a selective and potent EGFR kinase inhibitor with IC50 of 0.46 nM, 0.13 nM, 0.26 nM, 0.19 nM and 1.07 nM for for EGFRd746-750/T790M/C797S, EGFRL858R/T790M/C797S, EGFRd746-750/T790M, EGFRL858R/T790M and EGFRWT, respectively. TQB3804 (EGFR-IN-7) shows anti-tumor activity. |
|
|
S6805 |
Tyrphostin AG-528
|
Tyrphostin AG-528 (Tyrphostin B66) is a potent inhibitor of epidermal growth factor receptors (EGFR) and ErbB2/HER2 with IC50 of 4.9 μM and 2.1 μM, respectively. Tyrphostin AG-528 exhibits anticancer activity. |
|
|
S6809 |
SU5214
|
SU5214 is a inhibitor of VEGF receptor 2 (VEGFR2/FLK-1) with IC50 of 14.8 µM and EGFR with IC50 of 36.7 µm, respectively. |
|
|
S6813 |
Mobocertinib (TAK788)
|
Mobocertinib (TAK788, AP32788), an investigational TKI, is a potent, selective preclinical inhibitor of epidermal growth factor receptor (EGFR) and HER2 mutations. Mobocertinib (TAK788) is an antineoplastic agent. |
-
Lung Cancer, 2020, 152:135-142
|
|
S6868 |
Alflutinib (AST2818) mesylate
|
Alflutinib (AST2818, Furmonertinib) mesylate is a third-generation epidermal growth factor receptor (EGFR) inhibitor that inhibits both EGFR-sensitive mutations and T790M mutations. Alflutinib (AST2818), primarily metabolized by CYP3A4, is also a potent CYP3A4 inducer with EC50 of 0.25 μM. |
|
|
S6881New |
JND3229
|
JND3229 is a potent reversible inhibitor of EGFRC797S with an IC50 value of 5.8 nM. JND3229 also potently suppresses EGFRL858R/T790M and EGFRWT with IC50 values of 30.5 nM and 6.8 nM, respectively. |
|
|
S6897 |
Epertinib hydrochloride
|
Epertinib hydrochloride (S-222611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4 with IC50 of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride (S-222611 hydrochloride) exhibits antitumor activity. |
|
|
S6899 |
Licochalcone D
|
Licochalcone D (Lico D, LCD, LD), a flavonoid isolated from a Chinese medicinal plant Glycyrrhiza inflata, has antioxidant, anti-inflammatory and anti-cancer properties. Licochalcone D inhibit phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone D inhibits JAK2, EGFR and Met (c-Met) activities and induces ROS-dependent apoptosis. Licochalcone D also induces caspases activation and poly (ADP-ribose) polymerase (PARP) cleavage. |
|
|
S7000 |
AP26113-analog (ALK-IN-1)
|
AP26113-analog (ALK-IN-1) is an analog of AP26113 which is a potent and selective ALK inhibitor. It is also an inhibitor of EGFR. |
-
Clin Cancer Res, 2015, 21(1):166-74
-
Clin Cancer Res, 2014, 20(22):5686-96
-
Jpn J Clin Oncol, 2014, 44(10):963-8
|
|
S7039 |
PD168393
|
PD168393 is an irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773; inactive against insulin, PDGFR, FGFR and PKC. |
-
J Neurosci Res, 2021, 10.1002/jnr.24909
-
Int J Biochem Cell Biol, 2019, 115:105578
-
Theranostics, 2017, 7(3):664-676
|
|
S7206 |
CNX-2006
|
CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR. |
-
Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w
-
Cancer Sci, 2016, 107(4):461-8
|
|
S7284 |
Rociletinib (CO-1686)
|
Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2. |
-
Hum Cell, 2022, 10.1007/s13577-022-00671-y
-
Cancer Cell, 2021, S1535-6108(21)00383-4
-
Cancer Sci, 2021, 112(9):3784-3795
|
|
S7297 |
Osimertinib (AZD9291)
|
Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3. |
-
Nature, 2022, 603(7900):335-342
-
Mol Cancer, 2022, 21(1):43
-
Sci Adv, 2022, 8(4):eabi7711
|
|
S7298 |
AZ5104
|
AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1. |
-
J Pharm Biomed Anal, 2020, 177:112871
-
Clin Cancer Res, 2019, 25(8):2575-2587
-
Sci Rep, 2019, 9(1):5309
|
|
S7358 |
Poziotinib (HM781-36B)
|
Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2. |
-
JCO Precis Oncol, 2022, 6:e2100325
-
Hum Cell, 2022, 10.1007/s13577-022-00671-y
-
Cancer Cell, 2021, S1535-6108(21)00284-1
|
|
S7557 |
CL-387785 (EKI-785)
|
CL-387785 (EKI-785, WAY-EKI 785) is an irreversible, and selective EGFR inhibitor with IC50 of 370 pM.
|
-
J Biol Chem, 2017, 292(24):10112-10122
-
Nature, 2017, 550(7675):270-274
-
Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789
|
|
S7786 |
Erlotinib (OSI-774)
|
Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy. |
-
Sci Adv, 2022, 8(2):eabh3375
-
Cancer Res, 2022, canres.2445.2021
-
J Exp Clin Cancer Res, 2022, 41(1):58
|
|
S7810 |
Afatinib (BIBW2992) Dimaleate
|
Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy. |
-
Nature, 2022, 603(7900):335-342
-
Nat Immunol, 2022, 23(2):251-261
-
Adv Sci (Weinh), 2022, 10.1002/advs.202104055
|
|
S7824 |
Nazartinib (EGF816)
|
Nazartinib (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (L858R, ex19del) and T790M mt, with up to 60-fold selectivity over wild type (wt) EGFR in vitro. |
-
Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001
-
Transl Oncol, 2019, 12(5):705-713
-
J Thorac Oncol, 2019, 14(9):1556-1566
|
|
S7926 |
Lifirafenib (BGB-283)
|
Lifirafenib (BGB-283, Beigene-283) potently inhibits RAF family kinases and EGFR activities in biochemical assays with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant.
|
-
Nat Commun, 2020, 11(1):3157
-
Cell Rep, 2020, 31(11):107764
-
Cell Rep, 2019, 29(3):573-588
|
|
S7971 |
Zorifertinib (AZD3759)
|
Zorifertinib (AZD3759) is a potent, oral active, CNS-penetrant EGFR inhibitor with IC50 of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.
|
-
Oncogene, 2022, 10.1038/s41388-022-02256-3
-
Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7
-
Clin Cancer Res, 2019, 25(8):2575-2587
|
|
S8009 |
AG-18
|
AG-18 (RG-50810, Tyrphostin A23, TX 825) inhibits EGFR with IC50 of 35 μM. |
-
Reproduction, 2016, 151(2):179-85
|
|
S8036 |
Butein
|
Butein, a plant polyphenol isolated from Rhus verniciflua, is able to inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, also inhibits EGFR. |
-
Am J Cancer Res, 2020, 10(11):3721-3736
-
Oncotarget, 2015, 6(14):12637-53
|
|
S8229 |
Brigatinib (AP26113)
|
Brigatinib (AP26113) is a potent and selective ALK (IC50, 0.6 nM) and ROS1 (IC50, 0.9 nM) inhibitor. It also inhibits IGF-1R, FLT3, and mutant variants of FLT3 (D835Y) and EGFR with lower potentcy. |
-
NPJ Precis Oncol, 2022, 6(1):11
-
NPJ Precis Oncol, 2022, 6(1):5
-
Mol Pharmacol, 2022, MOLPHARM-AR-2021-000287
|
|
S8242 |
EAI045
|
EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor. |
-
Pharmazie, 2018, 73(11):630-634
|
|
S8294 |
Olmutinib (BI 1482694)
|
Olmutinib (BI 1482694) is a novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). Also a potent inhibitor of Bruton's tyrosine kinase. |
-
Ther Adv Med Oncol, 2022, 14:17588359221079125
-
Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001
-
Sci Rep, 2019,
|
|
S8362 |
Tucatinib (Irbinitinib, ONT-380)
|
Tucatinib (Irbinitinib, ONT-380, ARRY-380) is an oral, potent, selective, reversible and ATP-competitive small-molecule inhibitor of ErbB-2 (also called HER2) with IC50s of 8 nM and 7 nM for ErbB-2 and p95 HER2, respectively in cell-based assays, showing ~500-fold selective for HER2 vs EGFR. It has potential antineoplastic activity. |
-
Cell Metab, 2022, 34(1):90-105.e7
-
Breast Cancer (Dove Med Press), 2022, 14:25-39
-
Cancer Cell, 2021, S1535-6108(21)00284-1
|
|
S8412 |
Naquotinib(ASP8273)
|
Naquotinib (ASP8273) is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. |
-
Expert Opin Emerg Drugs, 2018, 10.1080/14728214.2018.1558203
Share on FacebookShare on TwitterShare on Google+
|
|
S8584 |
Theliatinib (HMPL-309)
|
Theliatinib (HMPL-309) is a highly potent EGFR inhibitor with Ki value of 0.05 nM against the wild type EGFR and IC50 values of 3 nM and 22 nM against EGFR and EGFR T790M/L858R mutant. It demonstrats 50 fold greater selectivity for EGFR compared to 72 other kinases. |
|
|
S8724 |
Lazertinib
|
Lazertinib (YH25448,GNS-1480) is a potent, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790M, L858R/T790M, Del19, L85R and Wild type EGFR respectively, showing much higher IC50 values aganist ErbB2 and ErbB4. |
-
Cancer Res Treat, 2021, 10.4143/crt.2021.385
-
J Thorac Oncol, 2019, 14(9):1556-1566
-
Mol Cancer Ther, 2018, 17(10):2257-2265
|
|
S8741 |
Avitinib (AC0010)
|
Avitinib (AC0010) is a pyrrolopyrimidine-based irreversible EGFR inhibitor that is mutation-selective with IC50 value of 0.18 nM against EGFR L858R/T790M double mutations, nearly 43-fold greater potency over wild-type EGFR (IC50 value, 7.68 nM). It has comparable anti-tumor activity and tolerated toxicity. |
|
|
S8814 |
TAS6417
|
TAS6417 (CLN-081, TPC-064) is a novel EGFR inhibitor that targets EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR. IC50 values ranges from 1.1 ± 0.1 to 8.0 ± 1.1 nmol/L. |
|
|
S8817 |
Almonertinib (HS-10296)
|
Almonertinib (Aumolertinib, HS-10296, Ameile) is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR. |
-
Biochem Pharmacol, 2021, 188:114516
|
|
S8852 |
Pyrotinib (SHR-1258) dimaleate
|
Pyrotinib (SHR-1258, BLTN, Pyrroltinib) dimaleate is a potent and selective irreversible dual tyrosine kinase inhibitor of EGFR and HER2 with IC50 of 0.013 μM and 0.038 μM, respectively. |
-
Transl Lung Cancer Res, 2021, 10(8):3659-3670
-
Biomed Chromatogr, 2021, e5221
-
Clin Transl Med, 2020, 10(8):e254
|
|
S8920 |
(Rac)-JBJ-04-125-02
|
(Rac)-JBJ-04-125-02 (JBJ-04-125-02 racemate) is a mutant-selective allosteric inhibitor of Epidermal growth factor receptor (EGFR) with potential anticancer activity. |
|
|
S8921 |
BI-4020
|
BI-4020 is an orally active, non-covalent EGFR inhibitor with IC50 of 0.6 nM and 0.2 nM for EGFRdel19 T790M C797S as biomarker potency and anti-proliferation potency in BaF3 cells, respectively. |
|
|
S9414 |
Cyasterone
|
Cyasterone is the main phytoecdysteroid component found in Cyathula capitata. It is a natural EGFR inhibitor and maybe a promising anti-cancer agent. |
|
|
S9711 |
CH7233163
|
CH7233163 is a non-covalent ATP competitive inhibitor of EGFR-tyrosine kinase with antitumor activities against tumor with EGFR-Del19/T790M/C797S. |
|
|
S9786 |
BDTX-189
|
BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. BDTX-189 exhibits anticancer activity. |
|
|
A5094 |
EGF Rabbit Recombinant mAb
|
EGF Rabbit Recombinant mAb detects endogenous levels of total EGF. |
|
|
S8312 |
NSC228155
|
NSC228155 is an activator of EGFR. It binds to the sEGFR dimerization domain II and modulates EGFR tyrosine phosphorylation. |
-
Free Radic Biol Med, 2022, S0891-5849(22)00053-3
-
Cell Death Dis, 2021, 12(2):173
-
Am J Transl Res, 2020, 12(5):2295-2304
|
|
S6530 |
EBE-A22
|
EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive. |
|
|
A2000 |
Cetuximab (anti-EGFR)
|
Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW:145.781 KD. |
- Adv Sci (Weinh), 2021, e2103360
- Nat Commun, 2021, 12(1):2335
- Environ Health Perspect, 2021, 129(2):27005
|
|
A2018New |
Panitumumab (anti-EGFR)
|
Panitumumab (anti-EGFR, ABX-EGF) is a recombinant, fully human IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR). |
|
|
E0368New |
DZD9008
|
DZD9008 is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR. |
|
|
S0070 |
Gefitinib-based PROTAC 3
|
Gefitinib-based PROTAC 3 which conjugates an EGFR binding element to a VHL ligand via a linker induces degradation of EGFR and mutants with DC50 of 11.7 nM and 22.3 nM in HCC827(Exon 19 del) and H3255 (L858R) cells, respectively. |
|
|
S0151 |
AG-1557
|
AG-1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. |
|
|
S0360 |
EGFR Inhibitor
|
EGFR inhibitor, a cell permeable, 4,6-disubstituted pyrimidine compound, is a highly selevtive inhibitor of EGFR kinase with IC50 of 21 nM. EGFR inhibitor directly depolymerizes microtubules and is used as a chemical probe to investigate both the EGFR pathway and microtubule dynamics. |
|
|
S0711 |
Canertinib dihydrochloride
|
Canertinib (CI-1033, PD-183805, compound 18) dihydrochloride is a potent and irreversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Canertinib dihydrochloride inhibits cellular EGFR and ErbB2 autophosphorylation with IC50 of 7.4 nM and 9 nM, respectively. |
- Acta Physiol (Oxf), 2021, 10.1111/apha.13661
- Sci Rep, 2017,
- BMC Cancer, 2017,
|
|
S1006 |
Saracatinib (AZD0530)
|
Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3. |
- Front Pharmacol, 2022, 13:807440
- Hum Cell, 2022, 10.1007/s13577-022-00671-y
- Cancer Cell, 2021, S1535-6108(21)00383-4
|
|
S1011 |
Afatinib (BIBW2992)
|
Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFRwt, EGFR L858R , EGFR L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy. |
- Nature, 2022, 603(7900):335-342
- Cancer Cell, 2022, S1535-6108(21)00662-0
- Nat Immunol, 2022, 23(2):251-261
|
|
S1019 |
Canertinib (CI-1033)
|
Canertinib (CI-1033, PD183805) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3. |
- Hum Cell, 2022, 10.1007/s13577-022-00671-y
- Nat Chem Biol, 2021, 10.1038/s41589-021-00947-8
- Acta Physiol (Oxf), 2021, 10.1111/apha.13661
|
|
S1023 |
Erlotinib HCl (OSI-744)
|
Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
- Sci Adv, 2022, 8(4):eabi7711
- Cancer Res, 2022, canres.2445.2021
- Ther Adv Med Oncol, 2022, 14:17588359221079125
|
|
S1025 |
Gefitinib (ZD1839)
|
Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway. |
- Mol Cancer, 2022, 21(1):43
- Sci Adv, 2022, 8(4):eabi7711
- Cell Death Dis, 2022, 13(2):136
|
|
S1028 |
Lapatinib (GW-572016) Ditosylate
|
Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. |
- Nat Chem Biol, 2022, 10.1038/s41589-022-00984-x
- Breast Cancer Res, 2022, 24(1):18
- Mol Cancer Ther, 2022, molcanther.0320.2021
|
|
S1046 |
Vandetanib (ZD6474)
|
Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS). |
- Cancer Res, 2022, canres.1397.2021
- Hum Cell, 2022, 10.1007/s13577-022-00671-y
- Cell Rep Med, 2022, 3(1):100492
|
|
S1054 |
AG99
|
AG99 (Tyrphostin 46,Tyrphostin A46,Tyrphostin B40) is a potent and selective inhibitor of EGFR. |
|
|
S1056 |
AC480 (BMS-599626)
|
AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc. Phase 1. |
- Genome Med, 2020, 18;12(1):17
- PLoS Genet, 2016, 12(9):e1006279
- Asian J Androl, 2016, 10.4103/1008-682X
|
|
S1079 |
PD153035 HCl
|
PD153035 HCl (SU-5271 HCl, AG1517 HCl, ZM 252868 HCl) is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM in cell-free assays; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src. |
- Int J Mol Sci, 2021, 22(8)3945
- FEBS Lett, 2021, 595(5):563-576
- FEBS Lett, 2021, 10.1002/1873-3468.14032
|
|
S1143 |
AG-490 (Tyrphostin B42)
|
AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src. |
- J Exp Med, 2022, 219(4)e20211498
- J Headache Pain, 2022, 23(1):25
- Mol Neurobiol, 2022, 59(5):3280-3293
|
|
S1167 |
CP-724714
|
CP-724714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc in cell-free assays. Phase 2. |
- Biochem J, 2021, BCJ20210173
- Int J Mol Sci, 2020, 22(1)E82
- NPJ Breast Cancer, 2020, 6:30
|
|
S1170 |
WZ3146
|
WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I). |
- Aging (Albany NY), 2020, 12(19):19022-19044
|
|
S1173 |
WZ4002
|
WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM in BaF3 cell line; does not inhibit ERBB2 phosphorylation (T798I). |
- Cancers (Basel), 2021, 13(16)4133
- Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w
- Cell Res, 2020, 10.1038/s41422-020-00409-1
|
|
S1179 |
WZ8040
|
WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I). |
- Biochemistry, 2018, 57(8):1369-1379
- Nat Commun, 2016, 7:10690
|
|
S1194 |
CUDC-101
|
CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1. |
- Cancer Sci, 2020, 112(1):133-143
- Anticancer Drugs, 2020, 31(2):158-168
- NPJ Breast Cancer, 2020, 6:30
|
|
S1342 |
Genistein (NPI 031L)
|
Genistein (NPI 031L), a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12μM or by insulin with IC50 of 19 μM. |
- Hum Cell, 2022, 10.1007/s13577-022-00671-y
- Adv Sci (Weinh), 2021, e2103360
- Nat Chem Biol, 2021, 10.1038/s41589-021-00772-z
|
|
S1392 |
Pelitinib (EKB-569)
|
Pelitinib (EKB-569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM. Pelitinib (EKB-569) also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282 nM, 800 nM and 1255 nM, respectively. Phase2. |
- Sci Rep, 2022, 12(1):2928
- Mol Cancer Ther, 2020, 5;molcanther.1131.2019
- Nat Cell Biol, 2019, 21(6):778-790
|
|
S1486 |
AEE788 (NVP-AEE788)
|
AEE788 (NVP-AEE788) is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2. |
- Cell Rep Med, 2022, 3(1):100492
- Genome Med, 2020, 18;12(1):17
- Mol Pharmacol, 2019, 95(5):528-536
|
|
S2111 |
Lapatinib (GW-572016)
|
Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death. |
- Cancer Discov, 2022, 12(1):204-219
- Cell Metab, 2022, 34(1):90-105.e7
- Nat Chem Biol, 2022, 10.1038/s41589-022-00984-x
|